Thursday, June 30, 2011
abstract: Cochrane Review - Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
BACKGROUND:Compared to patients without cancer, patients with cancer who receive anticoagulant treatment for venous thromboembolism are more likely to develop recurrent venous thromboembolism (VTE).
AUTHORS' CONCLUSIONS:LMWH (low molecular weight heparin) is possibly superior to UFH (unfractionated heparin) in the initial treatment of VTE in patients with cancer. Additional trials focusing on patient important outcomes will further inform the questions addressed in this review.
medical news: Sequence of ovarian genome identifies predominant gene mutations, points to possible treatment
"....While high-grade serous ovarian adenocarcinoma is conventionally considered as one type of cancer having uniform features, "we could divide the tumors into four different groups based on gene expression patterns," said Creighton. "They look like four different cancers."
"We were able to define a set of genes that were associated with worse outcomes versus better outcomes in patients," he said. They applied this gene signature to other sets of data collected about ovarian cancer and found that the profile predicted worse or better outcome there as well.
"These data are all public (blogger's note - refers to the Cancer Genome Atlas)," said Creighton. "They are meant for people to use to find specific genes for research. They could influence a lot of future studies."...cont'd
press release: UCSF-led team decodes evolution of skin and ovarian cancer cells (squamous cell/serous cell)
"They worked with a type of skin cancer known as cutaneous squamous cell carcinoma, which has among the highest numbers of mutations of any cancer, and also with a common type (blogger's note: assumption - serous cell type) of ovarian cancer."
"Using the new technique, the researchers were able to identify not just the mutations that differentiate two types of human cancer from normal cells, but the actual order in which some of the most key mutations occurred."
The article, "Temporal Dissection of Tumorigenesis in Primary cancers" is authored by Steffen Durinck, Christine Ho, Nicholas J. Wang, Wilson Liao, Lakshmi R. Jakkula, Eric A. Collisson, Jennifer Pons, Sai-Wing Chan, Ernest T. Lam, Catherine Chu, Kyunghee Park, Sung-woo Hong, Joe S. Hur, Nam Huh, Isaac M. Neuhaus, Siegrid S. Yu, Roy C. Grekin, Theodora M. Mauro, James E. Cleaver, Pui-Yan Kwok, Philip E. LeBoit, Gad Getz, Kristian Cibulskis, Jon C. Aster, Haiyan Huang, Elizabeth Purdom, Jian Li, Lars Bolund, Sarah T. Arron, Joe W. Gray, Paul T. Spellman, and Raymond J. Cho.
It appears in the July 2011 issue of the journal Cancer Discovery. See: http://dx.doi.org/10.1158/2159-8290.CD-11-0028
"Ovarian cancers generally show more complex karyotypic abnormalities than do cSCCs (13)."
"We sought to validate our observations in an additional
cancer type. Recently, full genomic sequence and copy number
changes were determined for 10 ovarian serous adenocarcinomas
by The Cancer Genome Atlas Project. Ovarian
cancers generally show more complex karyotypic abnormalities
than do cSCCs (13). In the 3 samples with a clear, informative
CN-LOH event at 17p, we again found solid evidence
for complete loss of TP53 as the earliest event (Fig. 1D). These
initial events in ovarian tumorigenesis could not have been
determined through sequencing of precursor lesions and invasive cancers (1, 14), as the asymptomatic nature of early
disease precludes tissue collection."
Pageviews last month: 9,414
Top 5 most popular posts (past month):